Introduction
Anagenex is a pre-clinical biotechnology innovator advancing drug discovery through its small molecule (directed evolution) platform. The company’s unique ML-driven technology enables Anagenex to discover first-in-class and best-in-class small molecule medicines addressing historically intractable targets.
%202%20(1).webp)
The Challenge
Anagenex had relatively little in the way of organizational structure or funding in place when Occam was engaged. The task was to help create a framework around which first time CEO, Nicolas Tilmans, could begin to realize his scientific ambitions to disrupt the way small molecule drugs are discovered at scale. At the same time we provided him with strategic guidance around board construction.
The Solution
In parallel, Occam successfully executed along both axes, recruiting a Board Chair as well as an operational heavyweight to lead all DEL creation. In Tito Serafini, Nicolas captured for his board an established, scientifically trained biotech CEO who had been through the same company-building exercise as Nicolas found himself in the midst of. At the same time, Occam provided a strategic perspective on organizational development. In Joe Franklin, an R&D operational heavyweight, Nicolas found an anchor around which he was able to then scale the infrastructure of Anagenex. *** Occam subsequently recruited Chief Scientific Officer Ryan Kruger (2023) and Chief Technology Officer Adrian Schreyer (2024).
Frequently Asked Questions
Occam Global provides global executive recruiting, board recruiting, and leadership advisory services.
With associates in New York, San Francisco, London, and Los Angeles, Occam serves clients across Europe the US, and Asia
We are specialists in recruiting executives and board members for the life sciences but serve a variety of other tech clients as well as venture capital.